Application

Camostat mesylate has been used to determine the effect of transmembrane protease, serine (TMPRSS) family proteases on cell-cell fusion.

Camostat mesylate may be used in cell signaling studies.

Biochem/physiol Actions

Camostat mesylate (CM) is used to treat pancreatitis and reflux esophagitis after gastrectomy.

Camostat mesylate inhibits the production of TNF-α and monocyte chemoattractant protein-1 (MCP-1) by monocytes. It also inhibits the activity of pancreatic stellate cells. Camostat mesylate regulates the cytokine expression and inflammation and is effective in the treatment of dibutyltin dichloride-induced rat pancreatic fibrosis.

Camostat is a synthetic, orally bioavailble serine protease inhibitor and airway epithelial sodium channel (ENaC) attenuator.

Features and Benefits

This compound is featured on the Acid-Sensing (Proton-gated) Ion Channels (ASICs) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Packaging

10, 50 mg in glass bottle